Clinical trials: Skin Carcinoma
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Breast Neoplasms, Carcinoma, Ductal, Breast
Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
A post-marketing study evaluating the transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs), in patients with functional and cosmetic breast deformities post segmental mastectomy or…
- Conditions
- Breast Neoplasms, Carcinoma, Ductal, Breast, Mammaplasty, Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,
- Trial name
- RESTORE-2 (NCT00616135)
- Testing
- ADRC-Enhanced Autologous Fat Transplant
- Where
- 5 sites in Belgium, Italy and 2 more
- Volunteers
- 71 people
- Sponsor
- Cytori Therapeutics
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Breast Cancer, Kidney Cancer
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00039052
- Testing
- interleukin-4 PE38KDEL cytotoxin
- Where
- 2 sites in United States
- Sponsor
- Neurocrine Biosciences
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Non-small Cell Lung Cancer, Colorectal Cancer
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT05935384
- Testing
- Guardant360
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- Guardant Health, Inc.
DCIS, Stage 0 Breast Cancer
The PREDICT Registry:
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions.
- Conditions
- DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
- Trial name
- NCT03448926
- Testing
- Treatment recommendation surveys, 7-gene biosignature
- Where
- 30 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- PreludeDx
Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
A phase 1a/1b, open-label, RM-1995 drug-dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of RM-1995 photoimmunotherapy treatment as…
- Trial name
- NCT05220748
- Testing
- RM-1995, Pembrolizumab
- Sponsor
- Rakuten Medical, Inc.
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
NSCLC, HNSCC
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of…
- Conditions
- NSCLC, HNSCC, Melanoma, Metastatic Cancer
- Trial name
- NCT05877430
- Testing
- CJRB-101, Pembrolizumab injection
- Where
- 4 sites in United States, South Korea
- Volunteers
- 160 people
- Sponsor
- CJ Bioscience, Inc.
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors, Hematologic Neoplasms
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with…
- Conditions
- Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors
- Trial name
- NCT03219268
- Testing
- tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 277 people
- Sponsor
- MacroGenics
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 10 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Cancer
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
The purpose of this study is to enable patients, who are currently receiving rogaratinib in a Bayer-sponsored clinical trial (incl. NCT01976741), to continue treatment after their respective study has been closed.
- Trial name
- NCT04125693
- Testing
- Rogaratinib (BAY1163877), Combination drug
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Bayer
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc